Testing considerations for phosphatidylinositol‐3‐kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer by Deborah L. Toppmeyer, Michael F. Press

Get full text

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer by Mridula A. George, Sadaf Qureshi, Coral Omene, Deborah L. Toppmeyer, Shridar Ganesan

Get full text

Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer by Elan Gorshein, Kant Matsuda, Gregory Riedlinger, Levi Sokol, Lorna Rodriguez-Rodriguez, Firas Eladoumikdachi, Miral Grandhi, Shridar Ganesan, Deborah L. Toppmeyer, Lindsay Potdevin, Kathleen Toomey, Kim M. Hirshfield, Nancy Chan

Get full text

Adapting and implementing breast cancer follow-up in primary care: protocol for a mixed methods hybrid type 1 effectiveness-implementation cluster randomized study by Sarah J. Fadem, Benjamin F. Crabtree, Denalee M. O’Malley, Lisa Mikesell, Jeanne M. Ferrante, Deborah L. Toppmeyer, Pamela A. Ohman-Strickland, Jennifer R. Hemler, Jenna Howard, Alicja Bator, Ayana April-Sanders, Rachel Kurtzman, Shawna V. Hudson

Get full text

Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes. by Madhura S Mehta, Sonia C Dolfi, Roman Bronfenbrener, Erhan Bilal, Chunxia Chen, Dirk Moore, Yong Lin, Hussein Rahim, Seena Aisner, Romona D Kersellius, Jessica Teh, Suzie Chen, Deborah L Toppmeyer, Dan J Medina, Shridar Ganesan, Alexei Vazquez, Kim M Hirshfield

Get full text